93 -2 (88) 2025 - Musahodzhaeva D.A., Azizova Z.Sh. - SERUM MARKERS OF INNATE IMMUNITY AND ANGIOGENESIS IN OVARIAN DYSFUNCTION OF VARIOUS GENESIS

SERUM MARKERS OF INNATE IMMUNITY AND ANGIOGENESIS IN OVARIAN DYSFUNCTION OF VARIOUS GENESIS

Musahodzhaeva D.A. - Institute of Human Immunology and Genomics of the Academy of Sciences of the Republic of Uzbekistan

Azizova Z.Sh. - Institute of Human Immunology and Genomics of the Academy of Sciences of the Republic of Uzbekistan

Ishmuratova L.E. - Institute of Human Immunology and Genomics of the Academy of Sciences of the Republic of Uzbekistan

Abdurasulova M.A. - Institute of Human Immunology and Genomics of the Academy of Sciences of the Republic of Uzbekistan

Resume

Ovarian dysfunction is a common cause of menstrual disorders and reduced fertility in women of reproductive age. This study aimed to assess serum levels of innate immunity, inflammatory and angiogenic markers in women with oligomenorrhea associated with polycystic ovary syndrome, endometriosis and uterine fibroids. A total of 70 women aged 22–40 years were examined, including patients with polycystic ovary syndrome, endometriosis and uterine fibroids, as well as a control group with regular menstrual cycles. Serum concentrations of MCP-1, VEGF-A and TGF-β1 were determined by enzyme-linked immunosorbent assay. Distinct nosology-specific immuno-angiogenic profiles were identified, reflecting differences in inflammatory activation, angiogenesis and reparative processes underlying ovarian dysfunction.

Key words: ovarian dysfunction, oligomenorrhea, innate immunity, angiogenesis, polycystic ovary syndrome, endometriosis, uterine fibroids.

First page

483

Last page

489

For citation:Musahodzhaeva D.A., Azizova Z.Sh., Ishmuratova L.E., Abdurasulova M.A. - SERUM MARKERS OF INNATE IMMUNITY AND ANGIOGENESIS IN OVARIAN DYSFUNCTION OF VARIOUS GENESIS//New Day in Medicine 2(88)2026 483-489 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

1. Artini PG, Monti M, Fasciani A, Tartaglia M, D’Ambrogio G, Genazzani AR, Cela V. Vascular endothelial growth factor, basic fibroblast growth factor and interleukin-8 in follicular fluid of patients with polycystic ovary syndrome during assisted reproductive cycles. Reprod Biol Endocrinol. 2006;4:9.
2. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
3. Bulun SE. Endometriosis. N Engl J Med. 2009;360(3):268–279.
4. Chegini N, Luo X, Ding L, Ripps BA. The expression of transforming growth factor-beta and TGF-beta receptors in human endometrium and endometriosis. Hum Reprod. 2003;18(11):2308–2316.
5. Fraser HM. Regulation of the ovarian follicular vasculature. Reprod Biol Endocrinol. 2006;4:18.
6. Fraser HM, Duncan WC. Vascular morphogenesis in the primate ovary. Angiogenesis. 2005;8(2):101–116.
7. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–1799.
8. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–231.
9. Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction. 2006;132(2):191–206.
10. Oakley OR, Kim H, El-Amouri I, Lin PC, Cho J. Distinct roles of macrophages in ovarian follicle development and ovulation. Am J Reprod Immunol. 2010;63(5):387–399.
11. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501–1512.
12. Wu MH, Hsiao KY, Tsai SJ. Endometriosis and possible inflammation markers. Gynecol Minim Invasive Ther. 2017;6(2):61–67.

    file

    download